+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Parkinson's Disease Therapeutics Market - Global Forecast 2026-2032- Product Image
Parkinson's Disease Therapeutics Market - Global Forecast 2026-2032- Product Image
Sale

Parkinson's Disease Therapeutics Market - Global Forecast 2026-2032

  • Report

  • 196 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 5134266
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Parkinson's Disease Therapeutics Market is projected to reach USD 6.14 Billion in 2026. It is expected to continue growing at a CAGR of 6.50%, reaching USD 8.98 Billion by 2032.

Parkinson's disease therapeutics address a progressive neurodegenerative disorder marked by motor symptoms such as tremor, rigidity, bradykinesia, and postural instability, as well as non-motor complications including sleep disruption, depression, autonomic dysfunction, constipation, pain, fatigue, and cognitive impairment.

The World Health Organization reports that global Parkinson's disease prevalence exceeded 8.5 million people in 2019 and has more than doubled over the past 25 years. This creates sustained clinical demand for levodopa-based regimens, dopamine agonists, MAO-B inhibitors, COMT inhibitors, amantadine, anticholinergics, device-aided therapies, rehabilitative care, and investigational disease-modifying approaches targeting underlying neurodegeneration.

Transformative Shifts in the Therapeutics Landscape

The Parkinson's disease therapeutics landscape is shifting from symptom control alone toward earlier diagnosis, personalized treatment sequencing, and longer-lasting delivery systems. Clinicians increasingly combine pharmacologic therapy with deep brain stimulation, infusion-based approaches, rehabilitation, speech and physical therapy, and digital monitoring to manage fluctuating disease burden and preserve daily function.

Pipeline activity is also moving toward alpha-synuclein biology, neuroinflammation, mitochondrial dysfunction, lysosomal pathways, gene therapy, cell therapy, and biomarker-guided trials. However, payers and health systems continue to require evidence of meaningful improvement in daily function, safety, adherence, caregiver burden, and total cost of care.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is creating cumulative value across Parkinson's disease drug discovery, clinical development, diagnosis, and care delivery. AI-enabled analytics can support target identification, molecule screening, patient stratification, imaging interpretation, speech analysis, gait assessment, tremor characterization, medication response tracking, and remote monitoring through wearable and smartphone-based data.

The strongest near-term impact is expected in trial enrichment and digital endpoints, where objective movement, sleep, speech, and activity data may reduce variability and improve sensitivity to treatment effects. Adoption still depends on clinical validation, explainable models, cybersecurity, representative datasets, physician workflow integration, and alignment with medical device and software regulatory requirements.

Key Regional Insights

North America remains a leading environment for Parkinson's disease therapeutics due to advanced neurology infrastructure, FDA-regulated innovation pathways, high diagnosis rates, clinical trial activity, and strong adoption of specialty drugs and device-aided care. Europe benefits from established movement disorder networks, EMA oversight, national reimbursement systems, health technology assessment, and active research in pharmacologic, surgical, digital, and rehabilitative Parkinson's disease care.

Asia-Pacific is gaining strategic importance as aging populations in Japan, China, South Korea, India, and Australia expand treatment demand and accelerate the need for neurologist access, essential medicines, and advanced therapies. Latin America, led by Brazil and Mexico, shows improving access through public health systems and expanding private care, although reimbursement and specialist availability remain uneven. The Middle East, especially GCC health systems, is investing in specialty hospitals, imported innovative medicines, and neurology centers, while Africa remains constrained by underdiagnosis, limited neurologist density, fragmented access to dopaminergic therapy, and affordability barriers.

Key Group Insights

The European Union and G7 anchor much of the global Parkinson's disease therapeutics innovation ecosystem through regulated clinical trials, academic neurology centers, pharmacovigilance systems, health technology assessment, and reimbursement for therapies with proven clinical value. NATO member countries also contribute through resilient medical supply chains, cross-border research collaboration, preparedness-focused health infrastructure, and standardized quality expectations across many advanced healthcare systems.

BRICS countries represent scale, manufacturing capacity, and expanding access to generics and affordable neurologic care, especially in China, India, and Brazil, while Russia emphasizes localized supply resilience. ASEAN markets are shaped by rising diagnosis, public hospital access, variable reimbursement, and growing demand for cost-effective Parkinson's disease medicines. GCC countries support premium specialty care, imported branded medicines, digital health adoption, and investment in neurology centers of excellence, strengthening access to advanced treatment pathways for eligible patients.

Key Country Insights

The United States leads commercial adoption through FDA approvals, specialist networks, Medicare coverage, movement disorder centers, and active clinical trials, while Canada emphasizes public reimbursement, guideline-based care, and equitable access across provinces. Mexico and Brazil show growing demand for affordable generics, expanded neurologic care, and improved continuity of treatment, with Brazil's public health system playing a central access role for essential medicines and specialist services.

In Europe, the United Kingdom, Germany, France, Italy, and Spain rely on health technology assessment, national reimbursement decisions, neurologist-led care pathways, and established use of levodopa and adjunctive therapies, while Russia focuses on localized supply resilience and access continuity. China is expanding access through hospital reform, reimbursement listing, domestic manufacturing, and broader neurology capacity; India is driven by high patient volume, generic availability, affordability considerations, and expanding specialist services in urban centers. Japan is shaped by super-aged demographics, high clinical awareness, and advanced management of motor complications, while Australia and South Korea combine strong reimbursement frameworks, modern neurology practice, and adoption of selected device-aided and digital care approaches.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize therapies that address motor fluctuations, dyskinesia, wearing-off, non-motor symptoms, adherence, safety, and caregiver burden. Strong differentiation requires real-world evidence, patient-reported outcomes, objective digital measures, and measurable functional benefit beyond traditional rating scales.

Organizations should pair pipeline investment with AI-enabled trial design, decentralized monitoring, biomarker strategies, and inclusive enrollment to reflect age, sex, ethnicity, disease stage, and comorbidity diversity. Market access teams need country-specific pricing, evidence, reimbursement, and affordability plans, while manufacturers should strengthen supply reliability for levodopa and other essential Parkinson's disease medicines to reduce treatment interruptions.

Research Methodology

This executive summary is based on triangulated secondary research from publicly available clinical, regulatory, epidemiologic, and health policy sources, including WHO disease burden data, national regulatory frameworks, treatment guidelines, peer-reviewed literature, clinical trial registries, pharmacovigilance references, and reimbursement information.

The analysis evaluates therapy classes, pipeline direction, regional access patterns, artificial intelligence adoption, digital health integration, technology use, and market access dynamics. Insights are validated through consistency checks across authoritative sources and interpreted using a structured healthcare market assessment framework focused on clinical relevance, regulatory context, access conditions, and evidence quality.

Conclusion

Parkinson's disease therapeutics will remain a high-priority healthcare category as prevalence rises with population aging and as patient needs expand beyond symptomatic motor control to include non-motor symptoms, long-term function, independence, and caregiver support. Current standards of care remain essential, but the competitive landscape is increasingly defined by delivery innovation, biomarkers, digital endpoints, and evidence-backed disease-modifying research.

Organizations that combine clinical differentiation, AI-enabled development, robust safety evidence, reliable supply, and region-specific access strategies will be best positioned to improve outcomes and create durable value in Parkinson's disease care.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Parkinson's Disease Therapeutics Market, by Drug Class
7.1. Introduction
7.2. Anticholinergics
7.2.1. Benztropine
7.2.2. Trihexyphenidyl
7.3. COMT Inhibitors
7.3.1. Entacapone
7.3.2. Tolcapone
7.4. Dopamine Agonists
7.5. Levodopa
7.6. MAO-B Inhibitors
8. Parkinson's Disease Therapeutics Market, by Therapy Type
8.1. Introduction
8.2. Medications
8.3. Non-Pharmacological Therapies
8.3.1. Deep Brain Stimulation
8.3.2. Physiotherapy
8.3.3. Speech & Language Therapy
9. Parkinson's Disease Therapeutics Market, by Route Of Administration
9.1. Introduction
9.2. Infusion
9.3. Injectable
9.4. Oral
9.5. Transdermal
10. Parkinson's Disease Therapeutics Market, by Targeted Area
10.1. Introduction
10.2. Atypical Parkinsonian
10.3. Drug-Induced Parkinsonism
10.4. Genetic Parkinson's
10.5. Idiopathic Parkinson’s
10.6. Vascular Parkinsonism
11. Parkinson's Disease Therapeutics Market, by Distribution Channel
11.1. Introduction
11.2. Offline
11.2.1. Hospital Pharmacy
11.2.2. Retail Pharmacy
11.3. Online
12. Parkinson's Disease Therapeutics Market, by End User
12.1. Introduction
12.2. Clinics
12.3. Home Care
12.4. Hospitals
13. Parkinson's Disease Therapeutics Market, by Region
13.1. Asia-Pacific
13.2. Europe
13.3. North America
13.4. Latin America
13.5. Africa
13.6. Middle East
14. Parkinson's Disease Therapeutics Market, by Group
14.1. NATO
14.2. G7
14.3. BRICS
14.4. European Union
14.5. ASEAN
14.6. GCC
15. Parkinson's Disease Therapeutics Market, by Country
15.1. United States
15.2. China
15.3. Germany
15.4. Japan
15.5. India
15.6. Canada
15.7. United Kingdom
15.8. Brazil
15.9. France
15.10. Mexico
15.11. Australia
15.12. Italy
15.13. South Korea
15.14. Russia
15.15. Spain
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
16.3.1. Concentration Ratio (CR)
16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025
17. Company Profiles
17.1. AbbVie Inc.
17.2. Acadia Pharmaceuticals Inc.
17.3. Novartis AG
17.4. UCB S.A.
17.5. Amneal Pharmaceuticals LLC
17.6. Otsuka Pharmaceutical Co., Ltd.
17.7. Sumitomo Pharma Co., Ltd.
17.8. Orion Corporation
17.9. Teva Pharmaceutical Industries Limited
17.10. H. Lundbeck A/S
17.11. Eisai Co., Ltd.
17.12. Amyl Therapeutics SRL
17.13. Apotex Inc.
17.14. Aspen Neuroscience, Inc.
17.15. Bayer AG
17.16. Biogen Inc.
17.17. BlueRock Therapeutics LP by Bayer AG
17.18. Brainstorm Cell Therapeutics Ltd.
17.19. Bristol-Myers Squibb Company
17.20. Cerevance, LLC
17.21. Cipla Limited
17.22. Denali Therapeutics Inc.
17.23. Eli Lilly and Company
17.24. F. Hoffmann-La Roche Ltd.
17.25. GlaxoSmithKline plc
17.26. Lupin Limited
17.27. Merck & Co., Inc.
17.28. Muna Therapeutics ApS
17.29. Pfizer Inc.
17.30. Torrent Pharmaceuticals Ltd.
17.31. Zydus Lifesciences Limited
List of Figures
FIGURE 1. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 7. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 11. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2025 VS 2032 (%)
FIGURE 13. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 15. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 17. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL ANTICHOLINERGICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL ANTICHOLINERGICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL ANTICHOLINERGICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL BENZTROPINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL BENZTROPINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL BENZTROPINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL TRIHEXYPHENIDYL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL TRIHEXYPHENIDYL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL TRIHEXYPHENIDYL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL COMT INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL COMT INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL COMT INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL ENTACAPONE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL ENTACAPONE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL ENTACAPONE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL TOLCAPONE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL TOLCAPONE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL TOLCAPONE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL DOPAMINE AGONISTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL DOPAMINE AGONISTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL DOPAMINE AGONISTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL LEVODOPA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL LEVODOPA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL LEVODOPA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL MAO-B INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL MAO-B INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL MAO-B INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL MEDICATIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL MEDICATIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL MEDICATIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL NON-PHARMACOLOGICAL THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL NON-PHARMACOLOGICAL THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL NON-PHARMACOLOGICAL THERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL DEEP BRAIN STIMULATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL DEEP BRAIN STIMULATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL DEEP BRAIN STIMULATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL PHYSIOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL PHYSIOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL PHYSIOTHERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL SPEECH & LANGUAGE THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL SPEECH & LANGUAGE THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL SPEECH & LANGUAGE THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL INFUSION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL INFUSION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL INFUSION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL TRANSDERMAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL TRANSDERMAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL TRANSDERMAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL ATYPICAL PARKINSONIAN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL ATYPICAL PARKINSONIAN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL ATYPICAL PARKINSONIAN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL DRUG-INDUCED PARKINSONISM MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL DRUG-INDUCED PARKINSONISM MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL DRUG-INDUCED PARKINSONISM MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL GENETIC PARKINSON'S MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL GENETIC PARKINSON'S MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL GENETIC PARKINSON'S MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL IDIOPATHIC PARKINSON’S MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL IDIOPATHIC PARKINSON’S MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL IDIOPATHIC PARKINSON’S MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL VASCULAR PARKINSONISM MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL VASCULAR PARKINSONISM MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL VASCULAR PARKINSONISM MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL ONLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL HOME CARE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL HOME CARE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL HOME CARE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 100. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 101. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 102. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2017-2032 (USD MILLION)
TABLE 103. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2017-2032 (USD MILLION)
TABLE 104. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 105. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 106. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 107. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2017-2032 (USD MILLION)
TABLE 108. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 109. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 110. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 111. EUROPE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 112. EUROPE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 113. EUROPE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2017-2032 (USD MILLION)
TABLE 114. EUROPE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2017-2032 (USD MILLION)
TABLE 115. EUROPE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 116. EUROPE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 117. EUROPE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 118. EUROPE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2017-2032 (USD MILLION)
TABLE 119. EUROPE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 120. EUROPE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 121. EUROPE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 122. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 123. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 124. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2017-2032 (USD MILLION)
TABLE 125. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2017-2032 (USD MILLION)
TABLE 126. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 127. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 128. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 129. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2017-2032 (USD MILLION)
TABLE 130. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 131. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 132. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 133. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 134. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 135. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2017-2032 (USD MILLION)
TABLE 136. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2017-2032 (USD MILLION)
TABLE 137. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 138. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 139. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 140. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2017-2032 (USD MILLION)
TABLE 141. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 142. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 143. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 144. AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 145. AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 146. AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2017-2032 (USD MILLION)
TABLE 147. AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2017-2032 (USD MILLION)
TABLE 148. AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 149. AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 150. AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 151. AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2017-2032 (USD MILLION)
TABLE 152. AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 153. AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 154. AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 155. MIDDLE EAST PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 156. MIDDLE EAST PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 157. MIDDLE EAST PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2017-2032 (USD MILLION)
TABLE 158. MIDDLE EAST PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2017-2032 (USD MILLION)
TABLE 159. MIDDLE EAST PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 160. MIDDLE EAST PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 161. MIDDLE EAST PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 162. MIDDLE EAST PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2017-2032 (USD MILLION)
TABLE 163. MIDDLE EAST PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 164. MIDDLE EAST PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 165. MIDDLE EAST PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 166. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 167. NATO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 168. NATO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 169. NATO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2017-2032 (USD MILLION)
TABLE 170. NATO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2017-2032 (USD MILLION)
TABLE 171. NATO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 172. NATO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 173. NATO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 174. NATO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2017-2032 (USD MILLION)
TABLE 175. NATO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 176. NATO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 177. NATO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 178. G7 PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 179. G7 PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 180. G7 PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2017-2032 (USD MILLION)
TABLE 181. G7 PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2017-2032 (USD MILLION)
TABLE 182. G7 PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 183. G7 PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 184. G7 PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 185. G7 PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2017-2032 (USD MILLION)
TABLE 186. G7 PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 187. G7 PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 188. G7 PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 189. BRICS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 190. BRICS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 191. BRICS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2017-2032 (USD MILLION)
TABLE 192. BRICS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2017-2032 (USD MILLION)
TABLE 193. BRICS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 194. BRICS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 195. BRICS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 196. BRICS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2017-2032 (USD MILLION)
TABLE 197. BRICS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 198. BRICS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 199. BRICS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 200. EUROPEAN UNION PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 201. EUROPEAN UNION PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 202. EUROPEAN UNION PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2017-2032 (USD MILLION)
TABLE 203. EUROPEAN UNION PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2017-2032 (USD MILLION)
TABLE 204. EUROPEAN UNION PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 205. EUROPEAN UNION PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 206. EUROPEAN UNION PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 207. EUROPEAN UNION PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2017-2032 (USD MILLION)
TABLE 208. EUROPEAN UNION PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 209. EUROPEAN UNION PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 210. EUROPEAN UNION PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 211. ASEAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 212. ASEAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 213. ASEAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2017-2032 (USD MILLION)
TABLE 214. ASEAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2017-2032 (USD MILLION)
TABLE 215. ASEAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 216. ASEAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 217. ASEAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 218. ASEAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2017-2032 (USD MILLION)
TABLE 219. ASEAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 220. ASEAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 221. ASEAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 222. GCC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 223. GCC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 224. GCC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2017-2032 (USD MILLION)
TABLE 225. GCC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2017-2032 (USD MILLION)
TABLE 226. GCC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 227. GCC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 228. GCC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 229. GCC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2017-2032 (USD MILLION)
TABLE 230. GCC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 231. GCC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 232. GCC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 233. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 234. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 235. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 236. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2017-2032 (USD MILLION)
TABLE 237. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2017-2032 (USD MILLION)
TABLE 238. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 239. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 240. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 241. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2017-2032 (USD MILLION)
TABLE 242. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 243. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 244. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 245. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 246. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 247. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2017-2032 (USD MILLION)
TABLE 248. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2017-2032 (USD MILLION)
TABLE 249. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 250. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 251. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 252. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2017-2032 (USD MILLION)
TABLE 253. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 254. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 255. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 256. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 257. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 258. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2017-2032 (USD MILLION)
TABLE 259. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2017-2032 (USD MILLION)
TABLE 260. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 261. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 262. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 263. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2017-2032 (USD MILLION)
TABLE 264. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 265. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 266. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 267. JAPAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 268. JAPAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 269. JAPAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2017-2032 (USD MILLION)
TABLE 270. JAPAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2017-2032 (USD MILLION)
TABLE 271. JAPAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 272. JAPAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 273. JAPAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 274. JAPAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2017-2032 (USD MILLION)
TABLE 275. JAPAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 276. JAPAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 277. JAPAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 278. INDIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 279. INDIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 280. INDIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2017-2032 (USD MILLION)
TABLE 281. INDIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2017-2032 (USD MILLION)
TABLE 282. INDIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 283. INDIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 284. INDIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 285. INDIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2017-2032 (USD MILLION)
TABLE 286. INDIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 287. INDIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 288. INDIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 289. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 290. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 291. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2017-2032 (USD MILLION)
TABLE 292. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2017-2032 (USD MILLION)
TABLE 293. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 294. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 295. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 296. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2017-2032 (USD MILLION)
TABLE 297. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 298. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 299. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 300. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 301. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 302. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2017-2032 (USD MILLION)
TABLE 303. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2017-2032 (USD MILLION)
TABLE 304. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 305. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 306. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 307. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2017-2032 (USD MILLION)
TABLE 308. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 309. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 310. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 311. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 312. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 313. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2017-2032 (USD MILLION)
TABLE 314. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2017-2032 (USD MILLION)
TABLE 315. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 316. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 317. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 318. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2017-2032 (USD MILLION)
TABLE 319. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 320. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 321. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 322. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 323. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 324. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2017-2032 (USD MILLION)
TABLE 325. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2017-2032 (USD MILLION)
TABLE 326. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABL

Companies Mentioned

  • AbbVie Inc.
  • Acadia Pharmaceuticals Inc.
  • Novartis AG
  • UCB S.A.
  • Amneal Pharmaceuticals LLC
  • Otsuka Pharmaceutical Co., Ltd.
  • Sumitomo Pharma Co., Ltd.
  • Orion Corporation
  • Teva Pharmaceutical Industries Limited
  • H. Lundbeck A/S
  • Eisai Co., Ltd.
  • Amyl Therapeutics SRL
  • Apotex Inc.
  • Aspen Neuroscience, Inc.
  • Bayer AG
  • Biogen Inc.
  • BlueRock Therapeutics LP by Bayer AG
  • Brainstorm Cell Therapeutics Ltd.
  • Bristol-Myers Squibb Company
  • Cerevance, LLC
  • Cipla Limited
  • Denali Therapeutics Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Lupin Limited
  • Merck & Co., Inc.
  • Muna Therapeutics ApS
  • Pfizer Inc.
  • Torrent Pharmaceuticals Ltd.
  • Zydus Lifesciences Limited

Table Information

Report AttributeDetails
No. of Pages196
PublishedSeptember 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 6.14 Billion
Forecasted Market Value ( USD ) by 2032 $ 8.98 Billion
Compound Annual Growth Rate6.5%
Regions CoveredGlobal
No. of Companies Mentioned31

Related Topics

Related Reports

Parkinson's Disease Drugs Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends (2026-2035) - Product Image

Parkinson's Disease Drugs Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends (2026-2035)

  • Report
  • 350 Pages
  • Global
From
Parkinson's Disease Drugs - Global Strategic Business Report - Product Image

Parkinson's Disease Drugs - Global Strategic Business Report

  • Report
  • 382 Pages
  • Global
From
Parkinson's Disease Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F - Product Image

Parkinson's Disease Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

  • Report
  • 185 Pages
  • Global
From
Parkinson's Disease Market Report 2026 - Product Image

Parkinson's Disease Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Anti-Parkinson Drugs Market Report 2026 - Product Image

Anti-Parkinson Drugs Market Report 2026

  • Report
  • 250 Pages
  • Global
From

About the Parkinson Drug Market

The Parkinson Drug market is a subset of the Central Nervous System Drugs market, which includes drugs used to treat neurological disorders. Parkinson's Disease is a progressive neurological disorder that affects movement, and is caused by a lack of dopamine in the brain. Parkinson Drugs are used to treat the symptoms of the disease, and can include levodopa, dopamine agonists, monoamine oxidase inhibitors, and catechol-O-methyltransferase inhibitors. These drugs can help to improve motor function, reduce tremors, and improve quality of life. The Parkinson Drug market is highly competitive, with many companies offering a range of treatments. Some of the major players in the market include AbbVie, GlaxoSmithKline, Merck, Novartis, Pfizer, and Teva Pharmaceuticals. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.